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Probiotics had been of interest in the promotion of good health in animals and man. Some of the 
positive effects of probiotics are: growth promotion of farm animals, protection of host from intestinal 
infections, alleviation of lactose intolerance, relief of constipation, anticarcinogenic effect, 
anticholesterolaemic effects, nutrient synthesis and bioavailability, prevention of genital and urinary 
tract infections, and immunostimulatory effects. Their beneficial effects may be mediated by direct 
antagonism of specific groups of organisms, resulting in a decrease in numbers or by an effect on their 
metabolism or by stimulation of immunity. The resistance of people in developing countries to diseases 
can be improved upon by promoting the consumption of locally fermented foods that are rich in 
probiotic organisms. This article reviews the potential of probiotics as immuno-enhancing agents and 
the future perspective in developing potent probiotics with immunostimulatory molecules that can 
serve as outstanding vaccine adjuvants. 
 





The human race and other animals have survived these 
many centuries because they are equipped with various 
defensive mechanisms (Amos, 1981). Some of these 
mechanisms are of general nature and serve to protect 
against many types of harmful agents and are on this 
basis referred to as non-specific immunity. A good 
example of this is phagocytosis of bacteria by specialised 
cells. Other defensive mechanisms are specific in that 
each is effective against a certain noxious agent and no 
other, and are therefore referred to as specific immunity 
(Stewart and Beswick, 1977). Higher animals have 
evolved an adaptive or acquired immune response that 
provides a flexible specific and more effective reaction to 
different infections (Roitt, 1984). 
The vertebrate host does not depend solely on its 
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Other defence mechanisms, which could be mechanical 
such as the unbroken skin, and to a lesser extent, 
mucous membranes provide a physical barrier to the 
entrance of most pathogens. The effectiveness of these 
barriers is often enhanced by the presence of chemical 
barriers as well (Stewart and Beswick, 1977). Tears, 
saliva, and the secretions of the nasopharynx contain 
lysozome, an enzyme that digest the peptidoglycan of 
bacterial cell walls. Ecological controls which involve the 
normal body flora, exist in a balance state and thereby 
protect the host from invasion by pathogens (Van. der 
Waaij et al., 1982). 
The home guard in the digestive tract are what we call 
‘friendly’ bacteria. These are bacteria that fight off the 
potentially pathogenic ones such as Escherichia coli and 
keep our intestinal tracts ‘in balance’. When friendly 
bacteria are not at the appropriate levels, and when 
unfriendly bacteria dominate, health problems such as 
production of gas, bloating, intestinal toxicity, 
constipation, and malabsorption of nutrients can occur.    
Infectious microorganisms act in certain ways that allow 




them to cause disease. These actions include gaining 
access to the host, adhering to and colonising cell 
surfaces, invading tissues, and producing toxins and 
other harmful metabolites (Brock and Madigan, 1991). 
The host however can thwart the efforts of pathogenic 
organisms from causing disease by their defence 
mechanisms. In the war of survival, if the pathogen wins, 
a complementary preventive and control measures will be 
needed.  
Chemotherapeutic agent had been in use since the 
1950s until its use was found to result to the development 
of resistant populations of bacteria, which made 
subsequent administration of antibiotics for therapy 
difficult (Fuller, 1989). The use of antibiotics as 
therapeutic agents had also been found to result in 
intestinal upsets, which often follow oral treatment with 
these compounds. 
Innovative approaches had been tried as alternative to 
antibiotic and these includes using live biotherapeutic 
agents such as yeast (Saccharomyces spp.) and 
bacterial isolates (Lactobacillus spp., Bifidobacterium 
spp.) or faecal enamels (Fuller, 1992). These 
biotherapeutic agents are called probiotics. This review 
gives an overview of the beneficial effects of probiotics in 
animal and human health. It also look into the potential of 
probiotic organisms as biotherapeutic agents that can 
help improve host immunity to diseases through the 
stimulation of the innate immune system which is a highly 
effective set of conserved mechanisms used by 
multicellular organisms to recognise and counter the 
threat of microbial infections.   
 
 
History of probitics 
 
Microorganisms have been essential to food and alcohol 
fermentation for thousands of years. Over the last 
century, different microorganisms have been used for 
their supposed ability to prevent and cure diseases, 
leading to the coining of the term probiotics, or ‘pro-life’ 
(Lilly and Stillwell, 1965). The concept of probiotics 
evolved around 1900. At this time Henry Tissier, a French 
Paediatrician, observed that children with diarrhoea had 
in their stools a low number of bacteria characterised by 
a peculiar, Y shaped morphology. These “bifid” bacteria 
were, on the contrary, abundant in healthy children 
(Tissier, 1906). Nobel price-winning Elie Metchnikoff in 
1907 advocated that the consumption of lactobacilli helps 
in controlling endogenous intoxication (autointoxication) 
caused by wrong types of components in the intestinal 
flora. He pointed out that the long, healthy lives of 
Bulgarian peasants were the result of their consumption 
of fermented milk products. The works of Metchnikoff and 
Tissier were the first to make scientific suggestions about 
the probiotic use of bacteria. The first clinical trials were 
done in the 1930s on the effect of probiotics on 





A lot of research on probiotics had been carried out 
after that time and it is increasing steadily since then, but 
much of it is in Europe, Asia, and America, and of recent 
in South Africa. Presently, probiotics are available in a 
variety of food products and supplements. In the U.S.A., 
the food products containing probiotics are almost 
exclusively dairy products, fluid milk and yoghurt, due to 
the historical association of lactic acid bacteria with 
fermented milk (Koop-Hoolihan, 2001). The most 
frequently used bacteria in these products belong to the 
genera Lactobacillus, Bifidobacterium, and 
Streptococcus. 
There have been several definitions to the word 
probiotics over the years. Lilly and Stillwell in 1965 used it 
to describe substances produced by one protozoan which 
stimulates another, but Parker in 1974 described it as 
animal feed supplements which had a beneficial effect on 
the host animal by affecting its gut flora. Parker’s 
definition clearly mentions organisms and substances, 
which contribute to intestinal microbial balance. Fuller 
(1989) argued that the latter definition is too imprecise, 
since substances mentioned would include antibiotics. He 
later revised the definition as ‘a live microbial feed 
supplement, which beneficially affects the host animal by 
improving its intestinal microbial balance’. This new 
definition emphasises the importance of live cells as an 
essential component of an effective probiotic and 
removes the confusion created by the use of the word 
substances. Other workers had also given their own 
definition of the term probiotic. For instance, Donohue et 
al. (1998) described probiotic bacteria as viable bacteria 
when applied in single or mixed culture, exhibit a 
beneficial effect on the health of the host. This definition 
encompasses the application of either axenic or mixed 
culture in the treatment of disease. 
The most recent definition was by Schrezenmeir and 
De Vrese (2001). They defined probiotics as viable 
microbial food supplements which beneficially influence 
the health of the host. This new definition clearly points 
out the health promoting effect of probiotic agents. For 
clarity purpose, the following terms can be used to 
distinguish different probiotic microorganisms: 
 
Research strain: This is any generally regarded as safe 
(GRAS) microorganism being studied for probiotic 
application, but not commercially available in any market. 
 
Commercial strain: A strain produced on an industrial 
scale for commercial use, as a fresh product (fermented 
milk, juice etc) or nutritional supplement (capsules or 
sashes). 
 
Probiotic strain: Any generally regarded as safe 
(GRAS) microorganism (such as lactobacilli, 
bifidobacteria, streptococci, saccharomyces, etc) shown 
in published research to have one or more of the 





• In vitro adherence to epithelial cells. 
• In vitro antimicrobial activity 
• In vitro resistance to bile, hydrochloric acid, and 
pancreatic juice. 
• Anticarcinogenic activity (reduction of carcinogens) in 
clinical trials. 
• Immune modulation or stimulation in clinical trials. 
• Reduction of intestinal permeability in clinical trials.  
• Colonisation of the GIT in clinical trials. 
 
Implantable strain: Any microbial strain native to the 
GIT of man (that is, lactobacilli or bifidobacteria) shown to 
survive passage through the GIT (appear live in stool) or 
persist on biopsies of the GIT mucosa after cessation of 
feeding. 
 
Clinical strain: An implantable strain which has been 
shown to have one or more specific health benefits, and 
therefore have demonstrated clinical usefulness. Some 
examples of benefits that have been shown are reduced 
intestinal permeability, enhancement of immune 
functions, and treatment of infection.    
 
 
Composition of probiotics    
 
Probiotics can be compounded in various ways 
depending on the sort of use intended. They can either 
be included in the pelleted feed or produced in the form 
of capsules, paste, powder or granules which can be 
used for dosing animals directly or through their food 
(Fuller, 1989). Probiotic preparations may be made up of 
a single strain or may contain any number up to eight 
strains. The advantage of multiple strain preparations is 
that they are active against a wide range of conditions 
and in a wider range of animal species. 
Fuller (1989) listed the following organisms as species 
used in probiotic preparation: Lactobacillus bulgaricus, 
Lactobacillus plantarum, Streptococcus thermophillus, 
Enterococcus faecium, Enterococcus faecalis, 
Bifidobacterium species, and Escherichia coli. With the 
exception of L. bulgaricus and S. Thermophilus, all the 
other organisms are all intestinal strains. 
Lactobacilli, Streptococci and Bifidobacteria are the 
commonly used groups in the production of probiotics. 
The justification for the use of Lactobacilli stems from 
studies which show that when the gut flora develops after 
birth, as Lactobacilli increases, other components of the 
flora decrease (Smith, 1965). Fuller (1978) had also 
reported that Lactobacilli exert a controlling effect on E. 
coli in gnotobiotic chicks.   
 
 
Mode of action of probiotics             
 
The mechanisms by which probiotics exert their effects 
on the host  are  still  speculative  (Koop-Hoolihan, 2001).  




Their beneficial effects may be mediated by direct 
antagonistic effect against specific groups of organisms, 
resulting in a decrease in numbers or by an effect on their 
metabolism or by stimulation of immunity. Probiotics 
antagonise pathogens through production of antimicrobial 
and antibacterial compounds such as cytokines and 
butyric acid (DeVuyst and Vandamme, 1994; 
Kailasapathy and Chin, 2000); reduce gut pH by 
stimulating the lactic acid producing microflora 
(Langhendries et al. 1995); compete for binding and 
receptor sites that pathogens occupy (Fujiwara, 1997; 
Kailasapathy and Chin, 2000); improve immune function 
and stimulate immunomodulatory cells (Isolauri et al., 
1995; Rolfe, 2000); compete with pathogens for available 
nutrients and other growth factors (Rolfe, 2000); or 
produce lactase which aids in lactose digestion. 
 
 
Characteristics of good probiotics 
 
Fuller (1989) listed the following as features of a good 
probiotic: 
 
• It should be a strain, which is capable of exerting a 
beneficial effect on the host animal, e.g. increased 
growth or resistance to disease. 
• It should be non-pathogenic and non-toxic. 
• It should be present as viable cells, preferably in large 
numbers. 
• It should be capable of surviving and metabolising in 
the gut environment e.g. resistance to low pH and 
organic acids. 
• It should be stable and capable of remaining viable for 
periods under storage and field conditions. 
 
A probiotic agent with all these features has considerable 
advantage over antibacterial supplements such as 
antibiotics currently in use. They do not induce resistance 
to antibiotics, which will compromise therapy. They are 
not toxic and therefore will not produce undesirable side 
effects when being fed and in the case of food animals, 
will not produce toxic residues in the carcass. They may 
stimulate immunity whereas the immune status remains 
unaffected by antibiotics. 
An essential determinant in the choice of a probiotic 
microorganism is its ability to reach, survive, and persist 
in the environment in which it is intended to act (Marteau 
et al., 1992; Charles et al., 1998). 
 
 
Nutritional and health promoting effects of probiotics 
 
Modern nutrition is changing rapidly. In recent time, the 
focus of scientist has been to look into the health 
promoting effect of food apart from safe nutrient provision 
and overcoming deficiencies. It is anticipated that this 
kind of food called functional foods, will  contribute  to  an  




overall better state of health for the consumers. Probiotic 
preparations have served as functional foods in human 
and animal production for the past two decades. The 
beneficial effects of probiotic will depend on a number of 
factors including the strain chosen, level of consumption, 
duration and frequency of exposure, and the 
physiological condition of the individual (Koop-Hoolihan, 
2001). Some of the beneficial effects of the practical use 
of probiotics are: growth promotion of farm animals 
(Baird, 1977; Mordenti, 1986; Chang et al., 2001); 
protection of host from intestinal infections (Nurmi and 
Rantala, 1973; Pascual et al., 1999; Koop-Hoolihan, 
2001; Oyetayo et al., 2003); alleviation of lactose 
intolerance (Garvie et al., 1984; Jiang, 1996); relief of 
constipation (Alm et al., 1983; Graf, 1983); 
anticarcinogenic effect (Fuller, 1989; Walker and Duffy, 
1998; Zabala et al., 2001); anticholesterolaemic effects 
(Tahri et al., 1995; Bertazzoni et al., 2001); nutrient 
synthesis and bioavailability (Koop-Hoolihan, 2001); 
prevention of genital and urinary tract infections 
(Redondo-Lopez et al., 1990; Martin et al., 1999); 
immunostimulatory effects (Aattouri et al., 2001). 
 
        
Effects of probiotics on the immune system 
 
The focus of the present review is on the potentials of 
probiotics to stimulate the immune system of the host. It 
has been discovered that conventional animals with a 
complete gut flora have increased phagocytic activity and 
immunoglobulin levels compared with germ-free animals 
(Baalmear et al., 1984). Yoghurt has been shown to 
increase antibody levels when fed to germ free mice 
(Wade et al., 1984). Lactobacilli casei in particular was 
found to be active in the stimulation of phagocytic activity 
when administered to mice (Perdigon et al., 1986). For 
bacteria to be effective in the process of 
immunostimulation, it may be necessary for them to 
migrate from the gut to the systemic circulation. 
Lactobacilli had been found to be capable of translocating 
and surviving for many days in the spleen, liver, and 
lungs (Fuller, 1989).  
Immune modulation of blood leukocytes in humans by 
lactic acid bacteria (LAB) had also been observed 
(Schiffrin et al., 1997). Aattouri et al. (2001) reported that 
oral ingestion of LAB by rats increases lymphocyte 
proliferation and interferon production. They suggested 
that beneficial consequences might be obtained by an 
increase in resistance to some infections.  
Studies in rats and mice reveal that lactic acid bacteria 
administered orally increase the numbers of T 
lymphocytes, CD4+ cells and antibody-secreting cells, 
including those in the intestinal mucosa, and enhance 
lymphocyte proliferation, natural killer cell activity, IL-1, 
TNF and IFN- production, antibody production (including 
secretory IgA), phagocytic activity and the respiratory 





al., 1999). It has also been reported that not all strains of 
lactic acid bacteria are effective (Naidu et al., 1999). In a 
study on rats co-colonised with L. plantarum and E. coli, 
Herias et al. (1999) reported a higher circulating 
concentration of total IgA and of E. coli-specific IgA and 
IgM compared with rats which were colonised with E. coli 
alone. There was also increased expression of the IL-2 
receptor in the lamina propria. Though there had been 
several animal studies, the effects of probiotic bacteria on 




Conclusion and future research perspective 
 
The potential of probionts associated with fermented 
African foods and beverages, such as ogi and kunnu, to 
modulate host immunity is a very promising area of 
research. More emphasis should be on further screening 
of already discovered probiotics e.g L.plantarum isolated 
from ogi slurry (Oyetayo and Osho, 2004) and also new 
probiotic candidates from other sources. This will involve 
further in vitro and in vivo investigation to evaluate their 
potential as immunostimulatory agents. Furthermore, 
genetic engineering of already identified probiotics and 
those newly discovered to make them more efficacious 
should be pursued.  
Further studies should be focused on the mechanisms 
of action within system, which stimulate the in vivo 
effects. An understanding of the oligonucleotide 
sequence, which triggers innate immune system, will go a 
long way to help understand the mechanism by which 
immunostimulatory potentials of probiotics are mediated. 
This investigation will reveal which CpG motifs within 
probiotic DNA (CpG DNA) that is actually responsible for 
the stimulation of the immune system of humans. An 
understanding of the specific oligonucleotide sequence 
will help in developing synthetic oligonucleotides 
containing CpG motifs (CpG DNA), which are potent 
immunostimulatory molecules and outstanding vaccine 
adjuvants. This can be achieved by genetic modification 
of these probionts associated with fermented foods and 
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